Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466071 | 0.88 | MCL1 (0.44) | TSHRSMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL17420571 | 0.88 | HPGD (0.46) | TSHRSMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL30628190 | 0.88 | HPGD (0.46) | TSHRSMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL10347749 | 0.86 | TSHR (0.45) | TSHRSMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL23380346 | 0.85 | GPR35 (0.43) | TSHRSMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL30628232 | 0.85 | CES2 (0.42) | TSHRSMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL17420534 | 0.85 | CES2 (0.42) | TSHRSMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL16068855 | 0.84 | HSD17B2 (0.50) | TSHRALDH1A1MAPTMAPK1LMNA | |
| SCHEMBL30628203 | 0.84 | TAS1R3 (0.52) | TSHRSMN1; SMN2ALDH1A1MAPTHTT | |
| SCHEMBL11234163 | 0.84 | RAB9A (0.44) | TSHRSMN1; SMN2HPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-7902248-B2 | C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146625-A1 | C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus | BERTHEL STEVEN JOSEPH | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TSHR 952/4885SMN1; SMN2 3680/4885HPGD 1324/4885 |
| US-20080146625-A1 | C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus | GCK, PC, PCK2 | TSHR 2310/4885SMN1; SMN2 3315/4885HPGD 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.